Android Apple

Ensysce Biosciences, Inc. (NASDAQ:ENSC): Are Analysts Optimistic?

By Yahoo! Finance   |   4 months ago
Ensysce Biosciences, Inc. (NASDAQ:ENSC): Are Analysts Optimistic?

Ensysce Biosciences, a clinical-stage pharmaceutical company, is expected to breakeven in 2026 with a projected profit of US$32m. Analysts predict an 85% annual growth rate to achieve this milestone.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.